Heghine Khachatryan: New Insights on Thrombosis in BCR-ABL1 Negative Myeloproliferative Neoplasms
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Journal of Thrombosis and Haemostasis (JTH)’s post on LinkedIn, adding:
“New insights into thrombosis in BCR::ABL1-negative myeloproliferative neoplasms
Thrombosis remains the leading cause of morbidity and mortality in patients with Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs).
Understanding the molecular mechanisms underlying thrombotic risk is essential for improving both risk stratification and targeted therapeutic approaches.
A recent study published in the Journal of Thrombosis and Haemostasis demonstrates that dysregulation of HIF-1α–regulated and thromboinflammatory genes is associated with an increased thrombotic risk in patients with BCR::ABL1-negative MPNs.
In a cohort of 120 patients, increased expression of genes including SLC2A1 and SELP correlated with a history of thrombosis, supporting the concept that hypoxia signaling and thromboinflammation are integral components of MPN pathobiology.
These findings reinforce the growing evidence that thrombotic risk in MPN extends beyond conventional clinical predictors and is closely linked to molecular and inflammatory pathways.
Identification of such biomarkers may facilitate more precise risk assessment and contribute to the development of novel targeted therapeutic strategies.”
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Olga Morath et al., adding:
“Dysregulation of HIF-1α–regulated and thromboinflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms
In 120 MPN patients, SLC2A1 and SELP gene expression were independently linked to thrombosis, with higher expression in JAK2-mutated patients suggesting a JAK2–HIF pathway connection.”
Title: Dysregulation of HIF-1α–regulated and thromboinflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms
Authors: Olga Morath, Therese Wolfrum, Carl Crodel, Andreas Hochhaus, Thomas Ernst, Jenny Rinke
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning